KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2022)

Recursion Pharmaceuticals' Receivables history spans 3 years, with the latest figure at $2.8 million for Q4 2022.

  • For Q4 2022, Receivables fell 69.71% year-over-year to $2.8 million; the TTM value through Dec 2022 reached $2.8 million, down 69.71%, while the annual FY2022 figure was $2.8 million, 69.71% down from the prior year.
  • Receivables reached $2.8 million in Q4 2022 per RXRX's latest filing, down from $11.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $11.7 million in Q2 2022 to a low of $49000.0 in Q2 2021.
  • Average Receivables over 3 years is $5.5 million, with a median of $2.8 million recorded in 2022.
  • The largest YoY upside for Receivables was 23736.73% in 2022 against a maximum downside of 69.71% in 2022.
  • A 3-year view of Receivables shows it stood at $156000.0 in 2020, then surged by 5726.92% to $9.1 million in 2021, then plummeted by 69.71% to $2.8 million in 2022.
  • Per Business Quant, the three most recent readings for RXRX's Receivables are $2.8 million (Q4 2022), $11.6 million (Q3 2022), and $11.7 million (Q2 2022).